Drug research

TNX-103

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEFNCT05983250	TENX	Phase 3	Active not recruiting	2026-06-30Actual
Long-Term Open-Label Extension Study of Oral LevosimendanNCT07436689	TENX	Phase 3	Enrolling by invitation	2029-03Estimated
LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2NCT07288398	TENX	Phase 3	Recruiting	2028-06-30Estimated

TENXActive not recruitingPrimary completion: 2026-06-30 · Actual

Trial details

TENXEnrolling by invitationPrimary completion: 2029-03 · Estimated

Trial details

TENXRecruitingPrimary completion: 2028-06-30 · Estimated

Trial details

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.